Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267

Cancer Biology and Therapy

Volumn 11, Issue 9, 2011, Pages 826-838

  Kalra, Jessica ^a   Anantha, Malathi ^a   Warburton, Corinna ^a   Waterhouse, Dawn ^a   Yan, Hong ^a   Yang, Young Joo ^a   Strut, Dita ^a   Osooly, Maryam ^a   Masin, Dana ^a   Bally, Marcel B ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centre for Drug Research and Development   (Canada)

Author keywords

Ascites; Bioluminescence imaging; Breast cancer; Docetaxel; Intergrin linked kinase; Intracardiac; Metastasis; Orthotopic; Preclinical models

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; LUCIFERASE; QLT 0267; QLT0267; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASCITES; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INOCULATION; LOW DRUG DOSE; MONITORING; MORBIDITY; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OVARY; TUMOR CELL; TUMOR GROWTH; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZO COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; LUCIFERASES; LUMINESCENT AGENTS; MICE; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; REPRODUCIBILITY OF RESULTS; TAXOIDS; TRANSFECTION;

EID: 79955517624     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.9.15183     Document Type: Article

References (27)

1. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007; 170:793-804. (Pubitemid 47339349)
2. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009; 15:6148-57.
3. Cespedes MV, Casanova I, Parreno M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006; 8:318-29.
4. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004; 40:852-7. (Pubitemid 38519764)
5. Tseng W, Leong X, Engleman E. Orthotopic mouse model of colorectal cancer. J Vis Exp 2007; 10:484.
6. Hoffman RM. Invest New Drugs 1999; 17:343-59.
7. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9:4227-39. (Pubitemid 37204044)
8. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) 2006; 42:657-70. (Pubitemid 44901640)
9. Bergh J, Jönsson PE, Glimelius B, Nygren P. SBU-group. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40:253-81.
10. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, et al. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK) and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res 2009; 11:R25.
11. Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu GL, et al. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther 2008; 7:59-70.
12. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 2008; 121:3121-32.
13. Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 2008; 9:2603-16.
14. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004; 9:24-32.
15. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis. J Cell Biol 2000; 148:779-90.
16. Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman JF, et al. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 1996; 73:154-61.
17. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24:227-35. (Pubitemid 30132189)
18. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007; 104:13-9. (Pubitemid 46976633)
19. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004; 64:3479-85. (Pubitemid 38657921)
20. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-27. (Pubitemid 44854747)
21. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res 2004; 2:606-19. (Pubitemid 39557664)
22. Montel V, Suzuki M, Galloy C, Mose ES, Tarin D. Expression of melanocyte-related genes in human breast cancer and its implications. Differentiation 2009; 78:283-91.
23. Bachmeier BE, Nerlich AG, Mirisola V, Jochum M, Pfeffer U. Lineage infidelity and expression of melanocytic markers in human breast cancer. Int J Oncol 2008; 33:1011-5.
24. Zhang Q, Fan H, Shen J, Hoffman RM, Xing HR. Human breast cancer cell lines co-express neuronal, epithelial and melanocytic differentiation markers in vitro and in vivo. PLoS One 2010; 5:9712.
25. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma. Cancer Res 2009; 69:5292-3.
26. Conley FK. Development of a metastatic brain tumor model in mice. Cancer Res 1979; 39:1001-7. (Pubitemid 9135125)
27. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 2005; 4:1146-56. (Pubitemid 41149562)